The stock of ABVC BioPharma Inc (ABVC) has gone down by -13.07% for the week, with a -41.50% drop in the past month and a -24.99% drop in the past quarter. The volatility ratio for the week is 3.86%, and the volatility levels for the past 30 days are 8.37% for ABVC. The simple moving average for the past 20 days is -17.17% for ABVC’s stock, with a -25.81% simple moving average for the past 200 days.
Is It Worth Investing in ABVC BioPharma Inc (NASDAQ: ABVC) Right Now?
Moreover, the 36-month beta value for ABVC is 0.76. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABVC is 8.92M and currently, short sellers hold a 7.15% of that float. On May 24, 2024, ABVC’s average trading volume was 1.15M shares.
ABVC) stock’s latest price update
The stock of ABVC BioPharma Inc (NASDAQ: ABVC) has decreased by -9.57 when compared to last closing price of 1.03.Despite this, the company has seen a loss of -13.07% in its stock price over the last five trading days. globenewswire.com reported 2024-04-18 that FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company’s subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
ABVC Trading at -20.08% from the 50-Day Moving Average
After a stumble in the market that brought ABVC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.78% of loss for the given period.
Volatility was left at 8.37%, however, over the last 30 days, the volatility rate increased by 3.86%, as shares sank -33.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.99% lower at present.
During the last 5 trading sessions, ABVC fell by -11.39%, which changed the moving average for the period of 200-days by -60.16% in comparison to the 20-day moving average, which settled at $1.0993. In addition, ABVC BioPharma Inc saw -19.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABVC
Current profitability levels for the company are sitting at:
- -384.6 for the present operating margin
- -8.89 for the gross margin
The net margin for ABVC BioPharma Inc stands at -497.77. The total capital return value is set at -1.21. Equity return is now at value -233.43, with -95.10 for asset returns.
Based on ABVC BioPharma Inc (ABVC), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -1.22. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -3.13.
Currently, EBITDA for the company is -8.19 million with net debt to EBITDA at -0.21. When we switch over and look at the enterprise to sales, we see a ratio of 478.61. The receivables turnover for the company is 0.03for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.27.
Conclusion
To wrap up, the performance of ABVC BioPharma Inc (ABVC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
